News & Views

Tony Zingale, Noted Chief Executive Officer and Entrepreneur, Appointed as an Observer to the Board of Directors of Athos Therapeutics

LOS ANGELES, May 17, 2023 — Athos Therapeutics, Inc. (“Athos”), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small molecule therapeutics for patients with immune-mediated diseases and cancer, announced today that Tony Zingale, a veteran software executive, was appointed as an observer to the Board of Directors of Athos Therapeutics.

“Athos has innovation as their core driver of success,” said Mr. Zingale. “The Athos AI and machine learning drug discovery platform is incredibly unique, and I believe it has the potential to fundamentally impact the course of drug discovery and development. I’m delighted to take on this board observer role.”

“We are very pleased to welcome Tony as an observer to our Board of Directors,” said Dimitrios Iliopoulos, PhD, MBA, President & CEO. “Tony will contribute to the development of our computational and AI platform based on his software engineering background and exemplary experience as CEO of successful private and public software companies. We look forward to his continued input.”

“We are excited to welcome Tony Zingale as an observer to our Board of Directors,” said Allan Pantuck, MD, MS, FACS, Chairman, Founder & CMO.  “He brings decades of deep expertise and leadership in key areas such as software development and commercialization, capital markets and strategic implementation of technology-driven global businesses. I am confident that he will provide valuable perspectives as we continue to execute our strategy of developing safe, personalized drug therapies for cancer and autoimmune disorders.”

About Mr. Zingale

Tony Zingale has 40+ years of experience building profitable, high growth, enterprise software companies. He most recently served as the Executive Chairman of Jive Software, where he also served as CEO for 5 years. Jive was the pioneer of social collaboration and communication software that Tony led Jive to over $200M in revenue. Prior to Jive, Mr. Zingale was the CEO of Mercury Interactive, the worldwide leader of Business Technology Optimization solutions. He successfully grew Mercury to over $1B in annual sales and then engineered their $5B merger with Hewlett Packard. Prior to Mercury, Tony was the CEO of Clarify, the original CRM company, where he grew the Company to over $300M in revenue and then engineered its $2.1B acquisition. Mr. Zingale holds a Bachelor of Science degree in electrical and computer engineering and a Bachelor of Arts degree in business administration from the University of Cincinnati.

About Athos

The Mission of Athos Therapeutics is to develop first-in-class medications that will significantly impact the lives of patients with autoimmune disorders, chronic inflammatory diseases, and cancer. The Athos drug development platform begins with the interrogation of high-quality patient samples and data sourced from premier global hospital systems. Athos identifies novel drug targets (hubs) by integrating clinical and molecular datasets into the biological network of a disease (the disease interactome) and matches them to its small molecule computational chemistry platform. At Athos, we aim to disentangle the complexity of autoimmune and cancer biology by evaluating disease heterogeneity at the molecular level and develop precision-medicine therapeutics by implementing a systems biology approach and stratifying patients into specific molecular subtypes. Our analytical platform includes the Athos data lake, singular well-established omics workflows, and an integrative deep machine learning engine. The co-founders of Athos include one of the founders of Kite Pharma (acquired for $12B), the medicinal chemist behind two multi-billion-dollar FDA-approved drugs (Xtandi & Erleada), and the discoverer of the miR-124 drug target, currently in a Phase III IBD trial. Along with ATH-63, the Company’s lead drug compound for Inflammatory Bowel Disease, the Athos pipeline includes small molecule approaches for various autoimmune disease and cancer. 

Additional information about Athos Therapeutics can be found at


Athos Therapeutics, Inc.
Dimitrios Iliopoulos, President & Chief Executive Officer

SOURCE Athos Therapeutics, Inc.